Corporate Banner
Satellite Banner
Technology Networks Header
Friday, July 25, 2014
Technology Networks
 
Register | Sign in
Home Page>Products
  Product News
New High Resolution Accurate Mass LC-MS System Scans 50 Percent Faster than Predecessor
Monday, June 16, 2014
When it comes to pursuing breakthroughs in proteomics research, there’s no such thing as too much scanning speed, as long as data quality remains high. The latest addition to the industry-leading Q Exactive family of Thermo Scientific liquid chromatography-mass spectrometry (LC-MS) systems addresses this demand.

New Mass Spectrometric Immunoassay Consumables Enable Large Biomolecule Analysis
Monday, June 16, 2014
The new functionalized pipette tips feature proprietary microcolumn technology designed to enable enhanced, reproducible target purification and reduce complexity in biological samples prior to liquid chromatography-mass spectrometry (LC-MS) protocols.

Bruker Announces Powerful New Mass Spectrometry Systems and Solutions
Monday, June 16, 2014
The products for life-science research, clinical research, biopharma and applied markets were announced at the 62nd ASMS Conference on MS.

Noviplex™ Card Plasma Separator Technology Simplifies Plasma Sampling for MS-based Research
Monday, June 16, 2014
Noviplex Cards allow for rapid collection of a volumetric sample of plasma from an unmeasured amount of whole blood within minutes.

AB SCIEX Launches Innovative Solutions for Therapeutics Development and Analysis
Monday, June 16, 2014
Three New Tools Accelerate the Study of Intact Proteins and Peptide Mapping: BioPharmaView™ Software, the TripleTOF® 6600 System, and SWATH™ Acquisition 2.0.

AB SCIEX Next-Generation Proteomics Platform Transforms Proteomics Research
Monday, June 16, 2014
New TripleTOF® 6600 System with SWATH™ Acquisition 2.0 captures every detectable protein and peptide in every run for deep hnsights into the proteome.

Waters Progenesis QI for Proteomics Version 2.0 Unveiled at ASMS with New Features
Monday, June 16, 2014
Advanced LC-MS 'Omics analysis software for proteomics applications is more rapid and reliable than ever.

Avacta Sponsors 5th Annual Protein Formulation Development and Drug Delivery Forum
Tuesday, June 03, 2014
Company will showcase the capabilities of the Optim 2 instrument at the event.

New Precision Plus Protein™ Dual Color Standards Allow Easy Protein Identification in Gels and Blots
Monday, June 02, 2014
Bio-Rad Laboratories, Inc. announces the launch the new and improved Precision Plus Protein™ Dual Color Standards, the brightest protein marker available.

<< 1 2 3 4 5 6 7 >>
Showing Results 21 - 30 of 1224
Scientific News
Dutch Public-Private Partnership Invests 28 Million Euro on Research into Personalized Medicine
The Netherlands' three Top Institutes for life-science research announce a joint research target to bring personalized medicine closer to reality.
FDA Grants Orphan Drug Status for Quark's QPI-1002 for the Prophylaxis of DGF in Kidney Transplant Patients
Company completes enrollment and dosing in the dose-escalation safety portion of a Phase 1/2 study.
Oncolytics Biotech® Receives MHRA Approval to Conduct Phase 3 Trial for REOLYSIN®
Conducting the trials in U.S. and Europe will allow Company to access the physicians that have worked with REOLYSIN in head and neck cancers.
Shenogen and Chemizon Announce Drug Discovery Collaboration Focused on Oncology and Endocrine Disorders
The agreement will create small molecule therapeutics targeting modulators of the ER-alpha 36 receptor.
Dutch Public-Private Partnership Invests 28 Million Euro on Research into Personalized Medicine
The Netherlands' three Top Institutes for life-science research announce a joint research target to bring personalized medicine closer to reality.
FDA Grants Orphan Drug Status for Quark's QPI-1002 for the Prophylaxis of DGF in Kidney Transplant Patients
Company completes enrollment and dosing in the dose-escalation safety portion of a Phase 1/2 study.
Oncolytics Biotech® Receives MHRA Approval to Conduct Phase 3 Trial for REOLYSIN®
Conducting the trials in U.S. and Europe will allow Company to access the physicians that have worked with REOLYSIN in head and neck cancers.
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv